ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that on December 29, 2022, and in connection with the previously announced... | January 4, 2023
Michaelj Vasconcelles Compensation Committee Company Board Of Directors The Compensation Committee Immunogen Inc Executive Vice President Medical Affairs
Source: marketscreener.com